MSFrontier

RIS - EBVD

Environmental Risk Factors in Multiple Sclerosis Development: Epidemiological Study of EBV Infection and Vitamin D Deficiency in RIS Patients
CompletedEarly (CIS/RIS)NCT07256431

We could not find results for this trial

I know where the results are

What it found

No result found

We found no results in the registry or in papers.

This trial finished 2 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

  • Antibiody titration

What it measured

Main measures

  • Prevalence of EBV seropositivity in RIS patients

    Baseline

    Immune response

  • Serum vitamin D levels in patients with RIS

    Baseline

  • Disease activity in patients with RIS

    Baseline

Other measures (1)

  • Prevalence of EBV seropositivity in healthy controls

    Baseline

    Immune response

Who could take part

Early (CIS/RIS)

Inclusion Criteria: * RIS patients from the ProBioRIS study with sufficient serum residuals for vitamin D testing and complete EBV serology. * Healthy subjects who participated in the VDSS trial and who provided consent for the use, for basic research purposes, of human biological samples collected during the trial. Exclusion Criteria: • Insufficient sample

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

This is an ancillary study using samples collected in the ProBioRIS cohort (NCT06395662). The aim of the project is to highlight new biomarker candidates to assess the risk of conversion to clinically definite multiple sclerosis (CDMS) and disease activity (Evidence of Disease Activity) by taking into account demographic, clinical and MRI parameters. A cohort of healthy subjects will be integrated into the study to serve as a control population. We will study a panel of serum immunoglobulins targeting different Epstein Barr virus antigens to identify latency or reactivation phases. Identifying and prioritizing risk factors for clinical conversion to MS in radiologically isolated syndrome patients is of major importance for the implementation of personalized monitoring and treatment strategies, especially following the recent highlighting of the benefit of background treatments in patients at high risk of CDMS.

Loading reviews and guidelines…

Linked trials

Links found where a registry record names another trial's registry number.

History

    1. Started

      Aug 2023

    2. Main results due

      Jul 2024

    3. Finished

      Jul 2024

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error